COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been reported in association with the coronavirus disease 2019 preventative adenovirus vector-based vaccines ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) in hundreds of recipients across the globe. VITT is characterized by thrombosis, typically at unusual sites, low fibrinogen, and elevated plasma D-dimer, generally manifesting between 4 and 28 days following vaccination. Detection of anti-platelet factor antibodies using an enzyme-linked immunosorbent assay (ELISA) is often confirmatory. Although several similar principles subside in most diagnostic criteria for VITT, the presentation of a positive ELISA assay, use of expert hematology and neurology opinion, and exclusion of possible VITT cases outside the "standard" 4 to 28-day timeframe have contributed a lack of global standardization for defining VITT. Accordingly, the global and regional incidence of VITT differs according to the diagnostic pathway and case definition used. This has influenced the public perception of VITT's severity and the decision to use adenovirus vector-based vaccines for limiting severe acute respiratory syndrome coronavirus 2 infection. We hereby delineate the recognized pathogenic mechanisms, global incidence, discrepancies in diagnostic criteria, recommended treatments, and global implications to vaccine hesitancy from this coagulopathy.

Detection of Antibodies in Patients with COVID-19 by Rapid Chromatographic Immunoassay

Objective: Coronavirus disease-2019 (COVID-19) is a potentially fatal respiratory disease caused by SARS-CoV-2, which has occurred in a human pandemic. This study aims to assess the responses of IgM and IgG antibodies to the virus after 7-14 days following the onset of illness. Materials and Methods: A total of 95 cases, including 67 patients with COVID-19 (24 male and 43 female) and 28 healthy individuals without COVID-19 as the control group (7 male and 21 female), were selected in the present study. IgM and IgG antibodies for COVID-19 were evaluated using rapid chromatographic immunoassay (RCI). Results: RCI demonstrated that IgM antibody was found as positive in 67 patients (100%) after 7-14 days, whereas IgG antibody was found as positive in 56 patients (83.6%) after 7 days and 67 patients (100%) were positive after 14 days. Conclusion: According to the obtained results, RCI for IgM and IgG antibodies can be used to make a quick and accurate diagnosis of COVID-19 infections (English) [ FROM AUTHOR] Amaç: Koronavirüs hastalığı-2019 (COVID-19), bir insan pandemisi olarak ortaya çıkan, SARS-CoV-2 tarafından bulaşan, potansiyel olarak ölümcül bir solunum yolu hastalığıdır. Bu çalışma, hastalığın başlangıcından 7-14 gün sonra IgM ve IgG antikorlarının virüse karşı oluşan antikorları saptamayı amaçlamaktadır. Gereç ve Yöntem: Bu çalışmada COVID-19'lu 67 hasta (24 erkek ve 43 kadın) ve COVID-19'suz 28 sağlıklı birey (7 erkek ve 21 kadın) içeren kontrol grubu olarak olmak üzere toplam 95 olgu irdelendi. COVID-19 için IgM ve IgG antikorları, hızlı kromatografik immünoassay test (RCI) kullanılarak değerlendirildi. Bulgular: RCI ile 7-14 gün sonra 67 hastada (%100) IgM antikoru pozitif, 7 gün sonra 56 hastada (%83.6), 14 gün sonra 67 hastada (%100) IgG antikor pozitifliği saptandı. Sonuç: Elde edilen sonuçlara göre, RCI, IgM ve IgG antikorlarını değerlendirerek, COVID-19 enfeksiyonun hızlı ve doğru teşhisini sağlamak için kullanılabilir (Turkish) [ FROM AUTHOR] Copyright of Turkish Journal of Immunology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)